AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus
Oncology Drugs Will Be Growth Drivers
AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.
You may also be interested in...
AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.
The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.